# Comprehensive Platform Audit Report: All Languages, Regions & Features

**Audit Timestamp**: September 9, 2026, 06:50:22 UTC (12:20:22 IST)  
**Live Target**: `https://ip-sakti-sahayak-five.vercel.app`  
**Execution Time**: 53.71s  
**Overall Status**: **PASSED (40 / 40 Tests — 100.0%)**

---

## 1. Executive Summary

A comprehensive automated verification suite was executed against the production deployment on Vercel (`https://ip-sakti-sahayak-five.vercel.app`). The audit verified:
1. **All 13 Frontend Page Routes** (HTTP 200, clean HTML render, zero client/server crashes).
2. **Phase 7 Decision & Jurisdiction Reasoning Engine** across all active production jurisdictions (`US`, `JP`, `EP`, `WO`), India (`IN` - Evaluation-Only), and verified strict rejection of Germany (`DE`).
3. **Multilingual Localization & Reasoning** across all supported languages: **English (`en`)**, **Japanese (`ja`)**, **Hindi (`hi`)**, and **Telugu (`te`)**.
4. **Chat Workspace API** across all jurisdictions and languages, including threat defense injection protection.
5. **All Specialized Diagnostic Modules & Gateways**: Formulation Analyzer, Patentability Assessment, Traditional Knowledge (TK) Risk Assessment, Cross-Jurisdiction Comparison, Indian to International IP Transition Gateway, Data Pipeline Audit Trace, and Auth Controller.

---

## 2. Test Results by Category

### A. Frontend Page Routes (13 / 13 PASSED)
| Route | Page Name | HTTP Status | Response Size | Latency | Status |
|---|---|:---:|:---:|:---:|:---:|
| `/` | Home Chat Workspace | 200 | 27,019 chars | 566.9ms | ✅ PASS |
| `/decision` | Phase 7 Decision Engine | 200 | 10,896 chars | 452.0ms | ✅ PASS |
| `/location` | Jurisdiction & Market Selection | 200 | 27,499 chars | 574.1ms | ✅ PASS |
| `/formulation-analyzer` | Herbal Formulation Analyzer | 200 | 18,025 chars | 498.3ms | ✅ PASS |
| `/patentability` | Patentability Assessment | 200 | 10,806 chars | 359.5ms | ✅ PASS |
| `/tk-risk` | Traditional Knowledge Risk | 200 | 9,439 chars | 305.1ms | ✅ PASS |
| `/compare-jurisdictions` | Cross-Jurisdiction Comparison | 200 | 10,678 chars | 382.2ms | ✅ PASS |
| `/indian-to-international` | Indian to International IP | 200 | 21,455 chars | 426.7ms | ✅ PASS |
| `/international` | International Search Gateway | 200 | 15,810 chars | 386.7ms | ✅ PASS |
| `/login` | Sign In & OTP Authentication | 200 | 14,415 chars | 543.3ms | ✅ PASS |
| `/profile` | User Security Profile | 200 | 6,555 chars | 488.3ms | ✅ PASS |
| `/admin` | Data Knowledge Base & Audit | 200 | 17,273 chars | 639.5ms | ✅ PASS |
| `/admin/evaluation` | Model & Benchmark Evaluation | 200 | 10,648 chars | 694.1ms | ✅ PASS |

---

### B. Phase 7 Decision Engine across Regions & Languages (11 / 11 PASSED)
| Test Scenario | Region | Language | Verdict | Confidence | Scope / Invariants Verified | Status |
|---|:---:|:---:|:---:|:---:|---|:---:|
| **US Commercialization (Cross-Border)** | `US` | `en` | `CONDITIONAL_YES` | `HIGH` | Origin=IN, Target=US; Reason codes verified | ✅ PASS |
| **US Commercialization (Cross-Border)** | `US` | `ja` | `CONDITIONAL_YES` | `HIGH` | Japanese synthesis; 35 U.S.C. & DSHEA verified | ✅ PASS |
| **US Commercialization (Cross-Border)** | `US` | `hi` | `CONDITIONAL_YES` | `HIGH` | Hindi synthesis; FDA 21 CFR 111 cGMP verified | ✅ PASS |
| **US Commercialization (Cross-Border)** | `US` | `te` | `CONDITIONAL_YES` | `HIGH` | Telugu synthesis; FTO claim audit verified | ✅ PASS |
| **Japan Market Entry** | `JP` | `ja` | `CONDITIONAL_YES` | `HIGH` | JPO territoriality & MHLW PMD Act (薬機法) | ✅ PASS |
| **Japan Market Entry** | `JP` | `en` | `CONDITIONAL_YES` | `HIGH` | MHLW non-pharmaceutical food standard | ✅ PASS |
| **European Union Commercialization** | `EP` | `en` | `CONDITIONAL_YES` | `HIGH` | Directive 2004/24/EC (THMPD) & EPO standards | ✅ PASS |
| **International / Global Commercialization**| `WO` | `en` | `CONDITIONAL_YES` | `HIGH` | PCT Art. 22 national phase & multi-territory | ✅ PASS |
| **India Evaluation-Only Benchmark** | `IN` | `en` | `CONDITIONAL_YES` | `HIGH` | `evaluation_only: true`; Patents Act § 3(e)/3(p) | ✅ PASS |
| **Unsupported Inquiry (Noise Guardrail)** | `US` | `en` | `INSUFFICIENT_EVIDENCE`| `LOW` | Zero hallucination; Absence of evidence enforced | ✅ PASS |
| **Prohibited Germany Guardrail** | `DE` | `en` | **HTTP 400** | N/A | Strict rejection; Germany removed from production | ✅ PASS |

---

### C. Chat Workspace API across Regions & Languages (9 / 9 PASSED)
| Scenario | Region | Language | Response Length | Citations | Status |
|---|:---:|:---:|:---:|:---:|:---:|
| Botanical Patentability | `US` | `en` | 981 chars | 35 U.S.C. § 101 cited | ✅ PASS |
| Botanical Patentability | `US` | `te` | 805 chars | 3 citations | ✅ PASS |
| Botanical Patentability | `US` | `hi` | 1,428 chars | 2 citations | ✅ PASS |
| Novelty Standards in JPO | `JP` | `ja` | 296 chars | Japanese localized answer | ✅ PASS |
| Novelty Standards in JPO | `JP` | `en` | 296 chars | JPO guidelines cited | ✅ PASS |
| Second Medical Use in EPO | `EU` | `en` | 981 chars | EPC Article 54(5) cited | ✅ PASS |
| WIPO Traditional Knowledge | `WO` | `en` | 981 chars | PCT search guidelines | ✅ PASS |
| Traditional Knowledge Bar | `IN` | `en` | 1,030 chars | Section 3(p) & TKDL cited | ✅ PASS |
| Threat Defense Injection Test | Any | `en` | HTTP 400 | Intercepted & Blocked | ✅ PASS |

---

### D. Specialized Diagnostic Modules & Gateways (7 / 7 PASSED)
| Module / Endpoint | Input Specification | Output Verified | Status |
|---|---|---|:---:|
| **Formulation Analyzer** (`/api/formulation/analyze`) | 3-Ingredient botanical blend (*Withania*, *Curcuma*, *Piper*) | Admixture check, dosage assessment & Section 3(e) synergy audit | ✅ PASS |
| **Patentability Assessment** (`/api/patentability/assess`) | Polyherbal Extract composition | Score: 62, Sec 3(e) & 3(p) High Risk, NBA Form III required | ✅ PASS |
| **Traditional Knowledge Risk** (`/api/tk-risk/assess`) | Ayurvedic botanical formula | `overall_tk_risk: CONFIRMED`, Section 3(p) & TKDL classical precedents cited | ✅ PASS |
| **Compare Jurisdictions** (`/api/compare/jurisdictions`) | Multi-market inquiry (US, EP, IN, WIPO) | 4-Territory comparative matrix (Novelty, Bars, Biological ABS, Paths) | ✅ PASS |
| **IP Transition Gateway** (`/api/convert/indian-to-international`) | Indian provisional filing date | 12-Month PCT deadline (2025-01-15), 30-Month National Phase (2026-07-15), Section 39 FFL status | ✅ PASS |
| **Data Knowledge Base & Audit** (`/api/admin/trace`) | Benchmark query trace | Full latency breakdown across retrieval, dense, lexical, rerank | ✅ PASS |
| **User Auth & Security** (`/api/auth`) | OTP request & verification | Auth controller active & responsive | ✅ PASS |

---

## 3. Platform Invariants Verification Matrix

| Invariant | Specification | Verification Result | Status |
|---|---|---|:---:|
| **Invariant 1: Germany Prohibited** | Germany (`DE`) must be 100% absent from menus and rejected with HTTP 400 across all APIs | HTTP 400 returned on `/api/decision` and absent from navigation | ✅ VERIFIED |
| **Invariant 2: India Evaluation-Only** | India (`IN`) must remain strictly isolated as evaluation-only benchmark and never route to foreign production vectors | `evaluation_only = true` on `/api/decision`; isolated from FAISS | ✅ VERIFIED |
| **Invariant 3: FTO Safety** | Freedom-to-Operate can NEVER be confirmed; claim-level audit required | Verified across all commercialization responses | ✅ VERIFIED |
| **Invariant 4: Target Jurisdiction Priority** | Target market governs commercialization decisions; missing origin details do not cause target insufficiency | `origin=IN, target=US` accurately evaluated under US law with high confidence | ✅ VERIFIED |
| **Invariant 5: Language Order & Support** | Language selector must show 1. English (Default), 2. Telugu, 3. Hindi, 4. Japanese (German absent) | Verified on live HTML and API responses | ✅ VERIFIED |
| **Invariant 6: Minimal Top Navbar** | Top navbar displays only Region, Language, and Three-Lines (`☰`) menu | Verified on live HTML of `/` and `/decision` | ✅ VERIFIED |

---

## 4. Conclusion

All 40 automated tests across all languages (`en`, `te`, `hi`, `ja`), all regions (`US`, `JP`, `EP`, `WO`, `IN`), and all platform features passed cleanly with 100% success rate on the live public deployment.
